Supplementary Figure 3 from Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib
Year: 2023
Type: supplementary-materials
Abstract: PDF file, 75K, Dacomitinib response is marginally inversely correlated with relative HER3 mRNA levels.
Authors: Ondrej Kalous, Dylan Conklin, Amrita J. Desai, Neil A. O'Brien, Charles Ginther, Lee Anderson, David J. Cohen, Carolyn D. Britten, Ian Taylor, James G. Christensen, Dennis J. Slamon, Richard S. Finn
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4362533872